These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36799420)
1. The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. Gitto M; Villaschi A; Federici M; Condorelli G; Stefanini GG Curr Pharm Des; 2023; 29(7):481-493. PubMed ID: 36799420 [TBL] [Abstract][Full Text] [Related]
2. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis. Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687 [TBL] [Abstract][Full Text] [Related]
3. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. Gitto M; Vrachatis DA; Condorelli G; Papathanasiou K; Reimers B; Deftereos S; Stefanini GG Cardiovasc Hematol Agents Med Chem; 2022; 20(2):90-102. PubMed ID: 34370645 [TBL] [Abstract][Full Text] [Related]
4. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM Drugs Context; 2023; 12():. PubMed ID: 36660013 [TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy. Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551 [TBL] [Abstract][Full Text] [Related]
6. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387 [TBL] [Abstract][Full Text] [Related]
9. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations. Kotit S Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098 [TBL] [Abstract][Full Text] [Related]
10. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914 [No Abstract] [Full Text] [Related]
11. A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction. Epperson J; Athar ZM; Arshad M; Chen E Cureus; 2024 Apr; 16(4):e57380. PubMed ID: 38694659 [TBL] [Abstract][Full Text] [Related]
12. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458 [TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. Girerd N; Zannad F J Intern Med; 2023 May; 293(5):550-558. PubMed ID: 36871279 [TBL] [Abstract][Full Text] [Related]
15. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760 [TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512 [TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice. Erdem S; Titus A; Patel D; Patel NN; Sattar Y; Glazier J; Alraies MC Cureus; 2023 Apr; 15(4):e37310. PubMed ID: 37182087 [TBL] [Abstract][Full Text] [Related]
18. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124 [TBL] [Abstract][Full Text] [Related]
19. Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis. Chakrala T; Prakash RO; Kim J; Gao H; Ghaffar U; Patel J; Parker A; Dass B Am Heart J Plus; 2023 Apr; 28():100286. PubMed ID: 38511072 [TBL] [Abstract][Full Text] [Related]
20. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]